Hemay005 vs PF-07038124

NCT04839328 · Phase 3 · completed

The study randomized 306 participants to Hemay005 or placebo, with participants masked to treatment, and used the clinical PASI75 response as its primary endpoint. Because no comparative results or statistical analysis are posted, the primary endpoint cannot be assessed.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT05375955 · Phase 2 · completed

This was a randomized, quadruple-blind, vehicle-controlled Phase 2 trial with a hard clinical primary endpoint (IGA/PGA response at week 12) and an adequate sample size (263 participants). However, the primary comparison was only partly successful: in atopic dermatitis, neither PF-07038124 0.01% (23.8% vs 11.4%, p=0.0711) nor 0.03% (21.4% vs 11.4%, p=0.1290) reached statistical significance, while in plaque psoriasis the 0.03% (37.1% vs 8.8%, p=0.0028) and 0.06% (45.5% vs 8.8%, p=0.0003) doses did. Because the primary endpoint was split across two diseases and only one cohort met it, the overall result is mixed rather than a clean success, capping the evidence at moderate.